Search for: "Synthon Pharmaceuticals, Inc."
Results 1 - 20
of 27
Sorted by Relevance
|
Sort by Date
23 Mar 2008, 8:45 pm
KGaA Defendants: Synthon Pharmaceuticals, Inc., Synthon Holding B.V., Synthon B.V. and Synthon Laboratories, Inc. [read post]
15 Jul 2018, 8:44 pm
• Defendants: Alvogen Pine Brook, LLC; Synthon BV; Synthon Pharmaceuticals, Inc.; and Synthon S.R.O Claim: Infringement of U.S. [read post]
22 Jun 2009, 8:57 pm
Synthon Pharmaceuticals, Inc. et al. 5:09-cv-00264; filed June 17, 2009 in the Eastern District of North Carolina Infringement of U.S. [read post]
20 Apr 2008, 8:40 pm
Synthon Pharmaceuticals, Inc. et al. 5:08-cv-00179; filed April 11, 2008 in the Eastern District... [read post]
23 Mar 2008, 7:52 pm
Synthon Pharmaceuticals, Inc. et al. 5:08-cv-00150; filed March 20, 2008 in the Eastern... [read post]
1 Nov 2018, 2:59 am
Moonlight Brewing Company, Opposition No. 91222542 [Section 2(d) opposition to registration of MOONLIGHT BREWING COMPANY for beer [BREWING COMPANY disclaimed] in view of the registered mark MOONLITE for restaurant services, food items, and ancillary goods].November 13, 2018 - 1 PM: Peter Piper, Inc. v. [read post]
10 May 2011, 4:24 pm
LLC, Watson Pharmaceuticals, Inc., and Synthon Holding B.V., that it believes the companies violated federal law by failing to inform antitrust authorities about drug patent agreements involving Sanofi's insomnia drug Ambien CR. [read post]
19 Oct 2010, 8:05 pm
On the same day as FDA's decision, FDA approved a generic Ambien CR® 6.25 mg tablet (tentative approval for 12 mg tablet) filed by Actavis and tentative approvals for generic Ambien CR® 6.25 mg and 12 mg tablets filed by Synthon Pharmaceuticals, Inc. [read post]
24 Mar 2010, 4:45 am
Synthon Pharmaceuticals, Inc. [read post]
2 Sep 2009, 5:57 pm
: Jacobson v Celgene (Patent Baristas) Ultracet (Tramadol/Acetaminophen) – US: CAFC vacates Ultracet obviousness decision: Ortho-McNeil Pharmaceutical, Inc v Teva Pharmaceuticals (not precedential) (Patently-O) (Patent Docs) (SmartBrief) Viread (Tenofovir) – India: MSF announces Patent Office rejected patents on AIDS drugs Tenofovir and Darunavir (Intellectual Property Watch) [read post]
27 Apr 2010, 10:58 pm
Solstice International Partners et al (Docket Report) US: FTC annual report highlights the Commission’s patent settlement efforts (FDA Law Blog) Products Adcirca (Tadalafil) – US: Declaratory judgement of non-infringement and invalidity based on ANDA to manufacture generic Adcirca: Synthon v Eli Lilly et al (Patent Docs) Amrix (Cyclobenzaprine) – US: Mylan seeks declaratory judgment of noninfringement, unenforceability and invalidity of Amrix patent, based on… [read post]
9 Apr 2009, 7:52 am
(IP Think Tank) Brazilian public-private partnerships in the pharma industry (IP tango) EU: ECJ to rule on reference on SPC Regulation interpretation from Lithuania in Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras (The SPC Blog) India: Delhi High Court Dasatinib order: Is patent-drug regulatory linkage a necessity? [read post]
22 Mar 2007, 1:18 pm
Apotex, Inc. [read post]
15 May 2011, 2:54 pm
LLC, Watson Pharmaceuticals, Inc., and Synthon Holding B.V. notifying them that the Bureau believes the companies violated federal law by failing to inform antitrust authorities about patent agreements involving Sanofi’s insomnia drug AMBIEN CR (zolpidem tartrate) Tablets, but that instead of recommending that the FTC take enforcement action, it would issue advisory letters. [read post]
25 May 2015, 4:15 am
The parties have been back in court to fight over other patents, resulting in the decision Synthon B.V. v Teva Pharmaceutical Industries Ltd [2015] EWHC 1395 (Pat), which came out last week and which Darren reports in timely fashion.* When functionality cuts deep, it can be hard to handle: Yoshida appeal dismissedValentina's back again to pen on General Court's decision in Joined Cases C‑337/12 P to C‑340/12 P Pi-Design AG,… [read post]
7 Sep 2011, 4:22 am
Apotex (Patently-O) Glivec (Imatinib mesylate) – India: The Glivec patent saga – its raining recusals (Spicy IP) Glivec (Imatinib mesylate) – India: Supreme Court to hear Novartis challenge to India’s patent law (IP Watch) Lo Loestrin Fe (Norethindrone acetate / Ethinyl estradiol / Ferrous fumarate) – US: Warner Chilcott files patent infringement complaint against Lupin in response to Para IV certification (Patent Docs) Lumigan (Bimatoprost) – US: Allergan files… [read post]
3 Aug 2011, 3:31 am
Patent and Trademark Office (Orange Book Blog) (IP Watch) (KEI) (Patent Docs) (Patent Docs) (IP Spotlight) (Patently-O) (Inventive Step) (Patentology) (Patent Law Practice Center) (IPBiz) (Out-Law) (PharmaPatents) (Maier & Maier) (Patent Docs) (Patent Baristas) Memantine – EU: CJEU ruling rejects pre-65/65 authorisations: Case C-195/09 Synthon v Merz Pharma (The SPC Blog) (EPLAW) Modafinil – UK: EWHC: Constructing a case for infringing particle-size patents: Cephalon… [read post]
6 Apr 2011, 12:18 am
427/09 Generics (UK) Ltd v Synaptech Inc (The SPC Blog) Simcor (Niacin, Simvastatin) – US: Abbott files patent infringement complaint against Watson following Para IV certification filing (Patent Docs) Thalomid (Thalidomide) – US: Decision in Lannett Thalomid bioequivalence study sample antitrust lawsuit could reignite debate on generic drug availability and REMS restrictions (FDA Law Blog) Yasmin (Drospirenone, Ethinylestradiol) – UK: Bayer Yasmin patents survive patent… [read post]
17 Jun 2009, 10:46 am
But patent infringement does not require that one should be aware that one is infringing: "whether or not a person is working [an] … invention is an objective fact independent of what he knows or thinks about what he is doing": Merrell Dow Pharmaceuticals Inc v H N Norton & Co Ltd [1996] R.P.C. 76 , 90. [read post]
1 Jul 2009, 7:14 am
OHIM decision in Laboratorios Andrómaco, S.A. v OTC Pharma International B V (Class 46) India: Valgancyclovir hearings and the need for more transparency: Roche v Cipla (Spicy IP) Japan approves first follow-on biologic (Patent Docs) UK: Journal of Intellectual Property Law & Practice note on ‘Paediatric extensions: the requirement of a compliance statement’ on UK IPO decision in Merck and Co, Inc (The SPC Blog) US: Sen Nelson introduces s 1315 bill to… [read post]
